Home / Community / News / News

News

10/17/2017 - 5:00pm

To develop new therapies for patients living with myotonic dystrophy (DM), specific infrastructure and information needs to be in place to make clinical trials feasible. The information needed for CDM trials is likely to be different than that used for adult trials.

10/17/2017 - 3:35pm

After a year of outreach and education, MDF has successfully convinced the Social Security Administration (SSA) to list congenital myotonic dystrophy (CDM) in its Compassionate Allowances program, significantly easing the application and review process.

09/26/2017 - 3:29pm

AMO Pharma released interim results for a Phase 2a safety and toxicity study of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy.

09/18/2017 - 11:00am

New data is available on the frequency, progression and treatment of GI symptoms in DM1 and DM2.

09/18/2017 - 10:49am

A new review article assesses the current status of and recommends future directions for brain imaging studies in DM1.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.